We are honored to have had the opportunity to represent the rare liver diseases community at the Alpha-1 Foundation National Conference in Miami, Florida. The weekend was filled with transformative research and thought-provoking conversations.

The GLI Pediatric and Rare Liver Diseases team was thrilled to attend the BARE Symposium on May 10-11, 2024.

In April, GLI Program Director Kristin Hatcher was invited to engage with patient advocacy groups, industry partners, and patients during the PBC Foundation’s International Summit in Edinburgh, Scotland.

Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).

In February, GLI raised awareness and amplified the patient voice in discussions about transitions in care for rare liver diseases. Here are a few highlights.

It’s Rare Liver Diseases Month!

If you haven’t already, join us for the 2024 #RareAware multifaceted campaign, focusing on the theme of “Transitions in Care During.”